Posting: # 19951
As per Health canada guidance document, "To avoid study bias, comparative bioavailability studies should be conducted in such a way that the subjects are not aware of which product (test or reference) is being administered. Furthermore, the persons checking for adverse reactions and those conducting the bioanalysis of samples should not know the treatment sequence."
In this case, if adverse events is ongoing, analysis both analytical and statistical phase completed, shall we submit treatment or code in study report?
Upto which phase guidance is applicable?
After completion of statistical phase if adverse event is still ongoing, still we need to follow guidance?